The endocrine system uses hormones, chemical messengers released into the bloodstream, to coordinate activity across distant organs. Glands such as the pituitary, thyroid, adrenal glands, pancreas and gonads secrete hormones that regulate metabolism, growth, reproduction, stress responses and fluid balance. Hormone action depends on receptors, feedback loops and timing. Many hormones are controlled by negative feedback, where a rising level of one hormone suppresses its own release. Understanding this feedback logic is essential because clinicians interpret hormone measurements in light of what the body is trying to maintain. A single abnormal value is often less informative than the pattern across related hormones and the clinical picture, so endocrine reasoning is fundamentally integrative and relational.
Insulin is produced by beta cells in the pancreatic islets and released when blood glucose rises after eating. It signals muscle and fat cells to take up glucose, promotes glycogen storage in the liver and muscle, and suppresses hepatic glucose production. In type 1 diabetes, autoimmune destruction of beta cells leads to little or no endogenous insulin, so exogenous insulin is required for survival. In type 2 diabetes, tissues become less responsive to insulin, and the pancreas initially compensates by secreting more, but over time beta-cell function declines. Clinically, this distinction shapes treatment, because the underlying defect determines whether insulin replacement, insulin sensitization or other agents are most appropriate.
Common diagnostic tests include fasting plasma glucose, the two-hour plasma glucose during a standard oral glucose tolerance test, random plasma glucose with symptoms, and glycated hemoglobin, known as HbA1c, which reflects average glucose over roughly two to three months. Each test has strengths and limits. HbA1c can be less reliable in conditions affecting red blood cell turnover, such as anemia or certain hemoglobin variants, and it is not appropriate for every situation. Diagnosis usually requires confirmation, typically by repeating an abnormal result or using two different tests. Diagnostic criteria are set by professional bodies and revised periodically, so clinicians should consult current guidance rather than relying on memorized cutoffs alone.
Type 1 diabetes often presents in younger people, sometimes with rapid onset, weight loss, marked thirst, frequent urination and, in some cases, diabetic ketoacidosis. Type 2 diabetes more often develops gradually in adults with risk factors such as excess body weight, physical inactivity, family history and older age, although it is increasingly seen in younger people. Clinicians may use autoantibody testing, C-peptide measurement and clinical course to clarify the type, especially in adults or atypical presentations such as latent autoimmune diabetes. The distinction matters greatly because it determines whether insulin is needed immediately and how long-term management is structured. Classification should be reviewed as more information emerges, since the boundaries between types are not always sharp.
Diabetic ketoacidosis is a serious emergency characterized by hyperglycemia, ketone accumulation, metabolic acidosis and dehydration. Symptoms can include nausea, vomiting, abdominal pain, rapid breathing and altered consciousness. Immediate priorities include assessing airway, breathing and circulation, establishing intravenous access, restoring fluid volume, measuring blood glucose, electrolytes, bicarbonate or pH and ketones, and starting insulin with careful monitoring. Potassium levels must be checked closely because insulin drives potassium into cells and can cause dangerous hypokalemia. Management protocols vary between institutions, so staff should follow local protocols and specialist advice. This page is educational and does not replace the judgment of licensed clinicians managing an acutely unwell patient.
Hypoglycemia is a blood glucose level that is too low for normal function, commonly defined as below seventy milligrams per deciliter, though thresholds vary by context. Symptoms include sweating, tremor, palpitations, hunger, confusion, irritability and, in severe cases, seizure or loss of consciousness. For a conscious person, the usual approach is to give fast-acting carbohydrate, such as glucose tablets or juice, then recheck glucose after about fifteen minutes and repeat if still low, followed by a longer-acting snack once recovered. Severe hypoglycemia may require glucagon or emergency medical help. Patients and caregivers should be taught these steps, and clinicians should review medications that raise hypoglycemia risk, particularly sulfonylureas and insulin.
A structured annual review typically covers glycemic control using HbA1c and glucose records, blood pressure, lipid profile, kidney function through estimated glomerular filtration rate and urine albumin, eye screening for retinopathy, foot assessment for neuropathy and vascular disease, and weight and lifestyle. It also includes a review of medications, hypoglycemia experience, mental health and psychosocial needs, and the patient's goals. Many services use recall systems and checklists to ensure that no component is missed. The pathway is designed to detect complications early, when intervention is most effective. Individualized targets should be agreed with the patient, taking into account age, comorbidity, hypoglycemia risk and personal priorities, rather than applying one fixed target to everyone.
Clinical guidelines summarize research evidence and offer recommendations on diagnosis, targets, medication choice and monitoring. Major professional organizations publish and update diabetes guidance regularly, and clinicians are expected to stay informed about current versions. Guidelines are most useful as a starting framework, because they rarely account for every patient's circumstances, such as frailty, pregnancy, cultural preferences, cost or competing conditions. Strength of evidence varies across recommendations, and some areas rely heavily on expert consensus. Good practice therefore combines guideline knowledge with shared decision-making and local protocols. A clinician who understands why a recommendation exists is better placed to adapt it safely than one who applies it mechanically.
Glucose-lowering medications work through different mechanisms. Metformin reduces hepatic glucose output and improves insulin sensitivity and is often a first-line oral agent in type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion but carry a higher hypoglycemia risk. Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists act on incretin pathways, enhancing glucose-dependent insulin release. Sodium-glucose cotransporter two inhibitors lower glucose by increasing urinary glucose excretion and have cardiovascular and kidney benefits in some patients. Insulin is used in type 1 diabetes and in many people with type 2 diabetes. Selection depends on efficacy, safety, comorbidities, weight, cost and patient preference, and recommendations evolve as new evidence appears.
Multiple daily injections involve using pens or syringes to give basal long-acting insulin and mealtime rapid-acting insulin, usually several times each day. Insulin pump therapy delivers rapid-acting insulin continuously through a small catheter, with programmed basal rates and bolus doses for meals. Pumps can offer finer dosing flexibility and may reduce variability, but they require training, regular site changes and reliable backup plans, since a pump failure or infusion set problem can cause rapid hyperglycemia and ketosis. Injections are simpler and cheaper but less adjustable. Choice depends on the person's lifestyle, skills, motivation and access. Users should understand how to troubleshoot their device and always carry an alternative insulin supply.
Continuous glucose monitoring systems use a small sensor, usually worn on the skin, to measure interstitial glucose at regular intervals and display trends, often with alerts. They can reveal patterns invisible to occasional fingerstick testing, such as overnight lows, postmeal spikes and the effects of exercise or medication timing. Data can help adjust insulin doses and reduce hypoglycemia when used with clinician guidance. Limitations include a lag between blood and interstitial glucose, sensor accuracy that varies at extremes, and the need for confirmatory fingerstick testing when symptoms do not match readings. Users must also manage skin reactions and sensor calibration. Results should be interpreted within a broader management plan rather than in isolation.
Pregnancy places high demands on glucose control, and tight preconception management reduces the risk of congenital anomalies and early pregnancy complications. Medication choices must be reviewed carefully, since some agents that are acceptable for general use are avoided in pregnancy, and insulin is commonly preferred. Targets are typically stricter than in non-pregnant adults, and monitoring is more frequent, often including multiple daily checks and fetal surveillance. Hypoglycemia risk changes as insulin needs shift across the trimesters. Multidisciplinary care involving endocrinology, obstetrics and midwifery, along with dietetic and diabetes education support, is standard practice in many settings. Clinicians should follow current professional guidance for their jurisdiction, as recommendations are specific and evolving.
Safe injection practice centers on using a new sterile needle or pen needle for each injection, never sharing pens, lancets or devices between people, and disposing of sharps in approved containers. Clinicians should perform hand hygiene, clean the injection site with appropriate technique and avoid reusing single-use items. Multidose insulin vials used in clinical settings require strict controls, because contamination of a vial can expose several people to infection. Shared glucose meters and finger-prick devices should be cleaned and handled according to manufacturer and local infection control policies. Breaches have caused real outbreaks in healthcare settings, so staff training and audit are important. Patients should be taught these principles as well, since home practices affect risk.
Diabetes can cause peripheral neuropathy, which reduces sensation, and peripheral arterial disease, which impairs circulation. Together they can allow minor injuries, pressure points or infections to go unnoticed and progress to ulcers, infection or amputation. A routine foot assessment includes inspecting the skin for cracks, calluses, blisters and nail problems, checking deformity and pressure areas, assessing pulses and capillary refill, and testing protective sensation with a monofilament or similar tool. Footwear advice and education on daily inspection are essential. Patients with high-risk features may be referred to a multidisciplinary foot service. Prompt escalation of any ulceration, redness or swelling is important, because delayed treatment can have serious consequences.
Clear diabetes documentation records diagnosis, type, current medications and doses, recent glucose and HbA1c results, hypoglycemia episodes, complication screening dates and findings, and the agreed care plan. Notes should be accurate, timely and written so that another clinician can continue care safely. Privacy obligations require that patient information be accessed only for legitimate care purposes, stored securely and shared only with appropriate consent or legal basis, following the rules in the relevant jurisdiction. Sensitive details such as mental health or relationship information need particular care. Patients may have rights to access their records, and clinicians should be familiar with local policy on data protection. Good documentation supports both continuity of care and accountability.
Effective communication in diabetes care is collaborative and respectful of the person's knowledge, values and circumstances. Clinicians can use open questions, check understanding through teach-back, and agree on realistic goals that fit daily routines. Explanations should avoid jargon, and information should be given in manageable amounts. Structured education programs help people learn carbohydrate counting, insulin adjustment, sick-day rules and hypoglycemia management. Emotional aspects, including diabetes distress and stigma, deserve attention, because they strongly influence adherence. Shared decision-making means presenting options and their trade-offs rather than issuing directives. Written materials and follow-up contact can reinforce learning, and families may be included with the patient's consent.
Diabetes care often involves physicians, specialist nurses, dietitians, pharmacists, podiatrists, ophthalmology and renal colleagues, psychologists, and sometimes exercise specialists and social care staff. Each professional contributes distinct expertise: specialist nurses often deliver education and titrate therapy under protocols, dietitians provide nutrition planning, pharmacists review medication safety and interactions, and podiatrists manage foot risk. Clear role definitions, shared records and regular case discussion help prevent duplication and gaps. Roles vary by country and service, and professional scope is defined by regulation and local agreement. Teamwork is most effective when the patient is an active participant, and when each contributor understands when to escalate concerns to another member.
Referral is generally considered when diagnosis is uncertain, when the diabetes type is unclear, when glycemic control remains poor despite appropriate treatment, or when there is frequent or severe hypoglycemia. Specialist input is also valuable for pregnancy planning, complex insulin regimens, pump or advanced technology initiation, rapidly progressive complications, and co-existing endocrine disorders. Referral criteria differ between health systems, and local pathways should be followed. Timely escalation matters for safety, so clinicians should not delay referral when a patient is deteriorating. Good referral letters summarize the problem, investigations, treatments tried and specific questions, which helps specialist teams prioritize and respond efficiently.
Informed consent requires that the person understands the nature of a proposed treatment, its expected benefits, its risks such as hypoglycemia or device failure, alternatives including doing nothing, and their right to decline or withdraw. For intensive insulin therapy and technology such as pumps or closed-loop systems, the discussion should cover training commitments, monitoring demands and emergency planning. Capacity is assumed unless shown otherwise, and it may fluctuate with illness or medication. Where capacity is impaired, decisions should follow the applicable legal framework and the person's best interests, with their views considered. Consent is an ongoing process, and clinicians should revisit it as circumstances change. Documentation should reflect the conversation, not only the signature.
Scope of practice defines what a professional is legally and ethically permitted to do, and it is set by regulators, employers and professional standards. In diabetes care, some roles may adjust insulin doses under written protocols, initiate certain medications, or order investigations, while others focus on education, assessment or referral. Prescribing rights, controlled substance rules and device authorization vary by country and sometimes by individual competence sign-off. Clinicians should work within their training and authorization, seek supervision when uncertain and document decisions appropriately. Regulatory requirements change over time, so professionals should check current rules for their setting. This material is educational and does not define any individual's legal scope.